Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test new radiation drug for Tough-to-Treat prostate cancer

NCT ID NCT03042468

Summary

This study is testing different doses of an experimental drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to find the highest dose that can be given safely without causing severe side effects. Researchers will also check if the treatment helps control the cancer by measuring PSA levels and tumor scans.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Tulane Cancer Center Clinic

    New Orleans, Louisiana, 70112, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.